Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel and Bortezomib in Previously Treated NSCLC
NCT00362882Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jul 2006
- Primary completion
- Jul 2010
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib in non-small cell lung cancer (NSCLC), sponsored by National Cancer Institute. Started Jul 2006; status: completed.
02
Drugs
bortezomib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00362882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00362882.